I'm working in...
Arrow for button
Cross Arrow

I'm working in...

Role
Company
Select

Embracing AI, DEI Changes, Restrategizing Research Sites

Katrina Rice, Chief Delivery Officer, Biometrics, eClinical Solutions

DEI in 2026: Re-emerging as a Strategic Priority vs. Siloed Initiative

Looking back at 2025, administrative changes in DEI and regulatory rollbacks caused uncertainty and potential deprioritization of incentives for critical initiatives like inclusive patient recruitment for clinical trials. Moving into 2026, even with a reduced federal emphasis on explicit DEI programs, we will still see companies embracing the principles of diversity, equity, and inclusion in clinical trials; it will just look – and sound – different than before.

In 2026, rather than being a siloed initiative or labeled as “DEI”, these initiatives will be integrated into core business operations, seen as a strategic priority, rather than an optional initiative driven or removed by policy. One area we’ll see this is with clinical trials for GLP-1s. As demand continues to surge, diversity will undoubtedly be top of mind, playing a crucial role in regulatory reviews for these drugs. With weight control and management closely tied to socioeconomic factors, the influx of GLP-1s coming to market will only heighten the need for trials that are reflective of the real population, with diversity at the forefront of these initiatives.  


By submitting, you agree to the processing of your personal data by eClinical Solutions as described in our Privacy Policy.